-+ 0.00%
-+ 0.00%
-+ 0.00%
Insight Molecular Diagnostics Enrolls First Several Patients In Its GALACTIC Study Evaluating GraftAssure Molecular Test For Monitoring Rejection In Kidney Transplant Recipients
Share
Listen to the news

This study serves to introduce GraftAssure technology to new transplant centers and additionally builds validation data ahead of potential FDA authorization of GraftAssureDx, a kitted version of the company’s clinical assay.

iMDx seeks to deliver a best-in-class molecular diagnostic test kit, to expand and improve testing access for kidney transplant patients, which it anticipates will deliver new value in the estimated $3 billion addressable market for regulated transplant rejection testing.

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending